Krystal shines in epidermolysis bullosa

There are currently no approved therapies for the rare skin disorder epidermolysis bullosa, but two might soon hit the market in quick succession. Krystal Biotech today reported impressive top-line results from the pivotal Gem-3 trial of its topical gene therapy Vyjuvek, setting up a filing in the first half of next year.

The news comes not long after Amryt announced a three-month delay to the FDA’s review of its project, Filsuvez, to February 28, 2022. Two other EB gene therapies, from Abeona and Castle Creek, are due to yield pivotal data next year, so competition could get fiercer yet.